TAVR holds up in the real world, demonstrates cost-effectiveness

05/26/2013 | Healio · CardiovascularBusiness.com

Data presented at the EuroPCR conference suggest transcatheter aortic valve replacement with the CoreValve system from Medtronic continues to offer clinical benefits at one year in "real-world" cases. Addressing concerns about aortic regurgitation, researcher Dr. Stephen Brecker said, "We don't think there is a significant improvement in aortic regurgitation. What the data refute is that it is getting any worse." SCAI Past President Dr. Larry Dean called that finding "hypothesis generating" and said results overall were "remarkable for a high procedure success." A second study accounting for cost and quality of life metrics found TAVR cost-effective.

View Full Article in:

Healio · CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ